{"id":"NCT04498832","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","officialTitle":"Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-21","primaryCompletion":"2021-01-14","completion":"2021-01-14","firstPosted":"2020-08-05","resultsPosted":"2022-02-08","lastUpdate":"2023-10-03"},"enrollment":2100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Influenza Immunization","Healthy Volunteers"],"interventions":[{"type":"BIOLOGICAL","name":"High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)","otherNames":["QIV-HD"]},{"type":"BIOLOGICAL","name":"Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)","otherNames":["QIV-SD"]}],"arms":[{"label":"Group 1: QIV-HD","type":"EXPERIMENTAL"},{"label":"Group 2: QIV-SD","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition \\[HAI\\] geometric mean titers \\[GMTs\\] and seroconversion rates) that was superior to responses induced by QIV-SD for the 4 virus strains at 28 days post-vaccination in all participants.\n\nSecondary Objective:\n\n* To describe the immune response induced by QIV-HD and QIV-SD by HAI measurement method in all participants.\n* To describe the safety profile of all participants in each study group.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28","timeFrame":"Day 28 (post-vaccination)","effectByArm":[{"arm":"QIV-HD","deltaMin":309,"sd":null},{"arm":"QIV-SD","deltaMin":110,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":15},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":["36906404"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":1049},"commonTop":["Injection Site Pain","Injection Site Erythema","Myalgia","Injection Site Swelling","Headache"]}}